Key terms
About AWH
Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AWH news
Yesterday
7:31am ET
Aspira Women’s Health reports Q4 EPS (30c), consensus (45c)
Mar 25
8:20am ET
Aspira Women’s Health announces new time for Q4, 2023 results
Mar 25
6:13am ET
Aspira Women’s Health Updates CFO Compensation Agreement
Mar 21
4:22pm ET
Aspira Women’s Health Welcomes Sandra Milligan as President
Mar 18
8:11am ET
Aspira Women’s Health appoints Milligan as President
Feb 06
8:07am ET
Aspira Women’s Health announces OvaSuite distribution agreement in Philippines
Jan 31
7:23am ET
Aspira price target raised to $7.20 from $5.65 at Alliance Global
Jan 26
4:58am ET
Aspira Women’s Health Adjusts Warrant Terms Post-Split
Jan 26
4:58am ET
Aspira Women’s Health Executes Private Equity Placement
Jan 26
4:57am ET
Aspira Women’s Health Announces New Securities Offering Deal
Jan 25
8:17am ET
Aspira Women’s Health announces $5.5M registered direct offering
Jan 04
10:55am ET
Aspira Women’s Health to hold a virtual research and development day
Jan 04
4:55am ET
Aspira Women’s Health to hold a virtual research and development day
Jan 03
10:00pm ET
Aspira Women’s Health to hold a virtual research and development day
No recent news articles are available for AWH
No recent press releases are available for AWH
AWH Financials
Key terms
Ad Feedback
AWH Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AWH Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range